Westpac is now outperforming the financial sector as a whole, up more than 23% since December. Today, we make the long-term case for avoiding/selling WBC shares based on demographics and technology.
With the price of bitcoin being US$10,362 at time of writing, the case for buying bitcoin grows stronger the longer it hovers around the US$10K mark — that’s the punchline today.
Today we look at the prospects for future Myer share price growth, its progress on pivoting its business and its long-term outlook. We conclude that despite its recent uptick, the Myer share price may struggle to keep going up as a mid-cycle slowdown approaches.
Today, we look at the latest Elixinol news, along with recent announcements out of MGC and BOD. We conclude that Elixinol could encounter support in the coming weeks or months. Meanwhile, MGC and BOD remain exciting but more speculative cannabis plays.
At time of writing, the share prices of ASX-listed nickel stocks like Independence Group NL [ASX:IGO] and Western Areas Ltd [ASX:WSA] are surging on news that Indonesia will move to ban nickel ore exports by the end of December.
At time of writing, the share price of Lynas Corporation Limited [ASX:LYC] is down a further 4.96%, trading at $2.30. After shooting up towards the end of June, the Lynas share price has fallen sharply in the last two weeks as trade tensions ease (again). You can see the timing of Trump policy...
Big moves are afoot amongst central banks with China being the country most willing to fire the first shot in the war on cash.
At time of writing, the share price of A2 Milk Company Limited [ASX:A2M] is taking a big hit. It’s currently down 11.25%, trading at $14.20. After some negative momentum over the last two and half weeks and a brief surge, the A2 Milk share price has resumed this trend today with a large fall.
BHP’s results missed analyst expectations, despite a record full year total dividend of $US2.35 a share. We give you a quick rundown of the RBA’s forecast for iron ore prices and what BHP might do to pivot their business to more profitable resources.
At time of writing, shares of biotech giant CSL Limited [ASX:CSL] are trading up 4.95%, at $230.36. As a blue chip, the CSL share price has a strong proclivity to move with markets.